Ophthal Medical News about macular degeneration

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

New era for personalized medicine: the diagnosis and management of age-related macular degeneration
Clinical and Experimental Ophthalmology, 11/03/09

Baird PN et al. – Along with recent improvements in high throughput and relatively inexpensive genetic technologies, authors are now in a position to consider developing a presymptomatic, personalized approach towards the assessment, management and treatment of this disease. The authors explore the applicability and challenges of this approach if it is to become commonplace for guiding treatment decisions for individuals with pre–existing disease or for those at high risk of developing it.

<< Previous
Successful treatment of ligneous conjunctivitis with topical...

Next >>
When and how to strengthen the superior oblique muscle

Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration
Retina, 11/11/09 Relevance Score: 68%

Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial
Ophthalmology, 10/28/09 Relevance Score: 68%

siRNA therapeutics for age-related macular degeneration: promises and pitfalls
Expert Review of Ophthalmology, 10/22/09 Relevance Score: 68%

Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
American Journal of Ophthalmology, 10/07/09 Relevance Score: 67%

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections
Acta Ophthalmologica, 11/11/09 Relevance Score: 66%